Sou Hu Cai Jing·2025-06-07 00:39Core Points - *ST Shuangcheng (002693) reported a closing price of 8.22 yuan as of June 6, 2025, down 2.72% from the previous week [1] - The company achieved a market capitalization of 3.409 billion yuan, ranking 123rd out of 150 in the chemical pharmaceutical sector and 3924th out of 5148 in the A-share market [1] Company Announcements - *ST Shuangcheng's injectable paclitaxel (albumin-bound) ANDA received approval from the US FDA for market entry, and the company has received a total of 6 million USD in milestone payments [1] - The company signed a licensing and supply agreement, granting exclusive rights to Meitheal Pharmaceuticals, Inc. and Hong Kong King-Friend Industrial Co., Ltd. for the development and production of injectable paclitaxel (albumin-bound) (100mg/vial) in the US [1] - From October 2022 to April 2023, the company received 3 million USD in milestone payments from HKF, and in May 2025, the FDA approved the ANDA, leading to the first shipment to the US [1] - Recently, the company received the remaining 3 million USD in milestone payments, totaling 6 million USD, which will be recognized as deferred revenue according to accounting standards [1]